Navigation Links
Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine
Date:9/7/2018

Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies,” was published in the Archives of Pathology & Laboratory Medicine on August 31, 2018. Download the study here: https://bit.ly/2wMyIVb

Duchenne muscular dystrophy (DMD) is a rare, progressive, and fatal neuromuscular disease caused by dystrophin protein loss in muscle. To support investigational treatment approaches, Flagship applied its expertise and proprietary technology in digital tissue image analysis to develop an immunofluorescent scanning and digital image-analysis solution that enables analysis of all muscle fibers within a biopsy section as well as providing data on each individual fiber.

To validate the MuscleMap approach, the study compared high-powered microscopic field total fiber counts and dystrophin-positive fiber counts obtained by trained pathologists to data produced by the MuscleMap algorithm. The authors note that this work is the first to validate immunofluorescent scanning and digital tissue image analysis workflow with the rigor required to support clinical trials.

“These exciting results will support more effective clinical trials for examining myofibers dystrophin expression by driving a greater level of consistency and detail,” says Trevor D. Johnson, Flagship Biosciences CEO. “Flagship is proud to partner with pharmaceutical and biotech companies in the development of digital image analysis solutions, like MuscleMap, that support the treatment of challenging medical conditions such as DMD.”

Download the study here: https://bit.ly/2wMyIVb

About Flagship Biosciences
Flagship Biosciences Inc. delivers comprehensive tissue profiling for predictive diagnostics in drug therapy using an Artificial Intelligence (AI) enabled computational tissue analysis (cTA®) pathology analytics platform. Our intuitive data reporting gives researchers, clinicians, and drug developers the actionable information needed to drive better clinical results for patients. For more information on how Flagship accelerates drug development, please visit http://www.flagshipbio.com and follow Flagship on Twitter @FlagshipBio.

Read the full story at https://www.prweb.com/releases/flagship_s_digital_tissue_image_analysis_approach_validated_in_assessment_of_dystrophin_muscle_biopsies_findings_published_in_archives_of_pathology_laboratory_medicine/prweb15739001.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Digital Science & SciBite Join Forces to Harness Big Data for Life Sciences
2. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the March 2013 Digital Edition Now Available Online and in the App Store
3. Simagis Digital Web Pathology Launches Service Provider Network
4. Chemical Publishing Company Partners with Author Cloudware for a Digital eBook Distribution for Water Treatment, Waste Water Treatment, and Cooling Water Treatment Titles
5. New Digital Temperature Controllers with Ramp/Soak Capabilities
6. Three Dispensing Modes Featured in the New Masterflex I/P Digital Brushless Process Drives from Cole-Parmer
7. Bugs eye inspires hemispherical digital camera
8. Digital X-Ray Market worth $4.82 By 2018
9. Simagis Web Pathology Adds Fast Search Capability for Digital Slide Archives
10. Pursuit's Elissa Guerra and Eunjoo Pluenneke to Present on Mobile Strategy at Digital Pharma West Conference
11. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2019)... (PRWEB) , ... June 18, 2019 , ... Personalized ... Investigational New Drug (IND) application to the FDA for use of a person’s own ... as a treatment of osteoarthritis in the knee. This IND is the first ...
(Date:6/11/2019)... ... June 10, 2019 , ... Advancements with Ted ... episode, scheduled to broadcast 4Q/2019. Check your local listings for more information. , ... about how its technology facilitates laboratories to improve efficiency and quality of research ...
(Date:6/11/2019)... ... 11, 2019 , ... Veterinary Regenerative Medicine company, VetStem ... announced that their GMP facility for cell production is now approved by the ... is an important milestone for VetStem as it expands into contract cell manufacturing ...
(Date:5/31/2019)... ... 2019 , ... For many years, the primary forms of cancer treatment have ... Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR ... receptors known as “CARs”. The CAR enables the final product to produce chemicals in ...
Breaking Biology Technology:
(Date:8/14/2019)... ... ... Join Jonathan Riek, PhD, VP, Musculoskeletal & Metabolic Imaging, BioTel Research ... EDT to learn about two common imaging methods in NAFLD/NASH to aid with early ... diffuse liver disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided ...
(Date:8/9/2019)... ... August 09, 2019 , ... With a demand in ... and more patients will visit urgent care centers (UCC) in the coming years, according ... report, The Market for Urgent Care Centers , is a detailed look at ...
(Date:8/6/2019)... ... August 06, 2019 , ... The ... One plant-based food in particular quickly entered the limelight – meat alternatives. Yet, ... a thermogelling and emulsifying ingredient such as methyl cellulose. This ingredient is highly ...
Breaking Biology News(10 mins):